191 related articles for article (PubMed ID: 21538727)
1. Constitutive activation of nuclear factor-E2-related factor 2 induces biotransformation enzyme and transporter expression in livers of mice with hepatocyte-specific deletion of Kelch-like ECH-associated protein 1.
Cheng Q; Taguchi K; Aleksunes LM; Manautou JE; Cherrington NJ; Yamamoto M; Slitt AL
J Biochem Mol Toxicol; 2011; 25(5):320-9. PubMed ID: 21538727
[TBL] [Abstract][Full Text] [Related]
2. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver.
Wu KC; Cui JY; Klaassen CD
PLoS One; 2012; 7(7):e39006. PubMed ID: 22808024
[TBL] [Abstract][Full Text] [Related]
3. Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice.
Reisman SA; Csanaky IL; Aleksunes LM; Klaassen CD
Toxicol Sci; 2009 May; 109(1):31-40. PubMed ID: 19246624
[TBL] [Abstract][Full Text] [Related]
4. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.
Maher JM; Dieter MZ; Aleksunes LM; Slitt AL; Guo G; Tanaka Y; Scheffer GL; Chan JY; Manautou JE; Chen Y; Dalton TP; Yamamoto M; Klaassen CD
Hepatology; 2007 Nov; 46(5):1597-610. PubMed ID: 17668877
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice.
Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Takeda K; Utsunomiya H; Oda K; Warabi E; Ishii T; Osaka K; Hyodo I; Yamamoto M
Am J Physiol Gastrointest Liver Physiol; 2008 Oct; 295(4):G735-47. PubMed ID: 18687751
[TBL] [Abstract][Full Text] [Related]
6. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species.
Reisman SA; Yeager RL; Yamamoto M; Klaassen CD
Toxicol Sci; 2009 Mar; 108(1):35-47. PubMed ID: 19129213
[TBL] [Abstract][Full Text] [Related]
7. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARĪ±-, and Nrf2-null mice.
Aleksunes LM; Klaassen CD
Drug Metab Dispos; 2012 Jul; 40(7):1366-79. PubMed ID: 22496397
[TBL] [Abstract][Full Text] [Related]
8. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system.
Takaya K; Suzuki T; Motohashi H; Onodera K; Satomi S; Kensler TW; Yamamoto M
Free Radic Biol Med; 2012 Aug; 53(4):817-27. PubMed ID: 22732183
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet.
Zhang YK; Yeager RL; Tanaka Y; Klaassen CD
Toxicol Appl Pharmacol; 2010 Jun; 245(3):326-34. PubMed ID: 20350562
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity.
Okawa H; Motohashi H; Kobayashi A; Aburatani H; Kensler TW; Yamamoto M
Biochem Biophys Res Commun; 2006 Jan; 339(1):79-88. PubMed ID: 16293230
[TBL] [Abstract][Full Text] [Related]
11. Butylated hydroxyanisole induces distinct expression patterns of Nrf2 and detoxification enzymes in the liver and small intestine of C57BL/6 mice.
Luo L; Chen Y; Wu D; Shou J; Wang S; Ye J; Tang X; Wang XJ
Toxicol Appl Pharmacol; 2015 Nov; 288(3):339-48. PubMed ID: 26291391
[TBL] [Abstract][Full Text] [Related]
12. Initial response and cellular protection through the Keap1/Nrf2 system during the exposure of primary mouse hepatocytes to 1,2-naphthoquinone.
Miura T; Shinkai Y; Jiang HY; Iwamoto N; Sumi D; Taguchi K; Yamamoto M; Jinno H; Tanaka-Kagawa T; Cho AK; Kumagai Y
Chem Res Toxicol; 2011 Apr; 24(4):559-67. PubMed ID: 21384861
[TBL] [Abstract][Full Text] [Related]
13. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.
Cheng Q; Aleksunes LM; Manautou JE; Cherrington NJ; Scheffer GL; Yamasaki H; Slitt AL
Mol Pharm; 2008; 5(1):77-91. PubMed ID: 18189363
[TBL] [Abstract][Full Text] [Related]
14. Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver.
Hu M; Zou Y; Nambiar SM; Lee J; Yang Y; Dai G
Cell Cycle; 2014; 13(15):2349-58. PubMed ID: 25483186
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice.
Randle LE; Goldring CE; Benson CA; Metcalfe PN; Kitteringham NR; Park BK; Williams DP
Toxicology; 2008 Jan; 243(3):249-60. PubMed ID: 18078705
[TBL] [Abstract][Full Text] [Related]
17. Liver expression of Nrf2-related genes in different liver diseases.
Cheng ML; Lu YF; Chen H; Shen ZY; Liu J
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):485-91. PubMed ID: 26459724
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-transferase activity.
Reisman SA; Csanaky IL; Yeager RL; Klaassen CD
Toxicol Sci; 2009 May; 109(1):24-30. PubMed ID: 19246623
[TBL] [Abstract][Full Text] [Related]
19. Keap1 cysteine 288 as a potential target for diallyl trisulfide-induced Nrf2 activation.
Kim S; Lee HG; Park SA; Kundu JK; Keum YS; Cha YN; Na HK; Surh YJ
PLoS One; 2014; 9(1):e85984. PubMed ID: 24489685
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems.
Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Sugimoto H; Utsunomiya H; Oda K; Warabi E; Ishii T; Yamamoto M
Biochem Biophys Res Commun; 2009 Nov; 389(3):431-6. PubMed ID: 19732748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
